-

$undefined

N/A

(N/A)

Intensity Therapeutics NasdaqCM:INTS Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Location: 1 Enterprise Drive, Shelton, CT, 06484-4779, United States | Website: https://www.intensitytherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

5.554M

Cash

929K

Avg Qtr Burn

-3.211M

Short % of Float

2.56%

Insider Ownership

33.62%

Institutional Own.

13.87%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.